Why the study?
Does treatment with prostaglandin E1 precursors and co-factors improve clinical and biochemical markers in patients with active rheumatoid arthritis?
Does treatment with prostaglandin E1 precursors and co-factors improve clinical and biochemical markers in patients with active rheumatoid arthritis?
Treatment with prostaglandin E1 precursors and co-factors did not improve clinical symptoms or biochemical markers in patients with active rheumatoid arthritis.
No takes yet. Share an insight, caveat, or question.
No benefit from PGE1 precursors in active RA; leaves open efficacy questions for RCTs.
Hansen et al. (1983) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: